EYPT Live signaler | Maksimer profitt med Getagraph.com

SELG 115771 min ago

@ $29.50

Utstedt: 14 feb 2024 @ 21:25

Avkastning: -33.08%

Forrige signal: feb 14 - 19:36

Forrige signal: Kjøp

Avkastning: 0.61 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom...

Stats
Dagens volum	928 277
Gjennomsnittsvolum	998 732
Markedsverdi	983.66M
EPS	$-0.330 ( 2024-05-01 )
Neste inntjeningsdato	( $-0.420 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.85
ATR14	$0.0470 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Adage Capital Management, L.p.	Buy	0	Common Stock, par value $0.001 per share ("Common Stock")
2024-04-18	Cormorant Asset Management, Lp	Buy	186 521	Common Stock
2024-04-18	Cormorant Asset Management, Lp	Buy	395 244	Common Stock
2024-03-30	Paggiarino Dario A.	Buy	14 000	Common Stock
2024-03-30	Paggiarino Dario A.	Buy	30 570	Common Stock

INSIDER POWER
41.08
Last 98 transactions
Buy: 1 049 923 \| Sell: 467 144

Volum Korrelasjon

Lang: -0.51 (weak negative)

Kort: -0.36 (neutral)

Signal:(41.342) Neutral

EyePoint Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
BNIXU	0.939
WDAY	0.865
WRAP	0.861
MELI	0.858
GTEC	0.855
TNGX	0.85
ZS	0.849
GTLB	0.847
GLBZ	0.847
ATEC	0.839

10 Mest negative korrelasjoner
AMRB	-0.874
MMAC	-0.863
OZK	-0.841
RDI	-0.84
PLUS	-0.83
RBCAA	-0.829
TLMD	-0.819
MMLP	-0.812
ISPC	-0.808
III	-0.807

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

EyePoint Pharmaceuticals Korrelasjon - Valuta/Råvare

0.23
( neutral )

0.45
( neutral )

0.00
( neutral )

0.80
( moderate )

-0.12
( neutral )

EyePoint Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$46.02M
Bruttogevinst:	$41.39M (89.93 %)
EPS:	$-1.820

FY	2023
Omsetning:	$46.02M
Bruttogevinst:	$41.39M (89.93 %)
EPS:	$-1.820

FY	2022
Omsetning:	$41.40M
Bruttogevinst:	$33.08M (79.89 %)
EPS:	$-3.34

FY	2021
Omsetning:	$36.94M
Bruttogevinst:	$28.76M (77.86 %)
EPS:	$-4.55

Financial Reports:

No articles found.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.